At the time of writing, Indaptus Therapeutics Inc [INDP] stock is trading at $2.36, up 12.92%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The INDP shares have gain 22.92% over the last week, with a monthly amount glided 38.02%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 4, March 2024, Indaptus Therapeutics Announces Positive Results from Second Cohort of Phase 1 Trial; Company Initiates Multi-Dose Cohort. In a post published today on Yahoo Finance, • Positive data following completion of second cohort of Phase 1 trial of Decoy 20 leads independent Safety Review Committee to recommend initiating multi-dosing cohort.
From an analyst’s perspective:
For the past year, the stock price of Indaptus Therapeutics Inc fluctuated between $1.50 and $4.08. Indaptus Therapeutics Inc [NASDAQ: INDP] shares were valued at $2.36 at the most recent close of the market.
Analyzing the INDP fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.81, Equity is -0.72 and Total Capital is -1.06. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.12 points at the first support level, and at 1.88 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.60, and for the 2nd resistance point, it is at 2.84.
Indaptus Therapeutics Inc [INDP] reported earnings per share of -$0.47 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.55/share, meaning a difference of $0.08 and a surprise factor of 14.50%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.39 per share as compared to estimates of -$0.58 per share, a difference of $0.19 representing a surprise of 32.80%.
Ratios To Look Out For
It is important to note that Indaptus Therapeutics Inc [NASDAQ:INDP] has a current ratio of 7.12. As well, the Quick Ratio is 7.12, while the Cash Ratio is 6.75.
Transactions by insiders
Recent insider trading involved Anderson Glen R., 10% Owner, that happened on Aug 14 when 23934.0 shares were purchased. 10% Owner, Anderson Glen R. completed a deal on Aug 11 to buy 35064.0 shares. Meanwhile, 10% Owner Anderson Glen R. bought 44354.0 shares on Aug 10.
